Novel CIC Point Mutations and an Exon-Spanning, Homozygous Deletion Identified in Oligodendroglial Tumors by a Comprehensive Genomic Approach Including Transcriptome Sequencing

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Eisenreich, Sophie ^a   Abou El Ardat, Khalil ^a   Szafranski, Karol ^b   Campos Valenzuela, Jaime A ^a   Rump, Andreas ^a   Nigro, Janice M ^c   Bjerkvig, Rolf ^c   Gerlach, Eva Maria ^a   Hackmann, Karl ^a   Schröck, Evelin ^a   Krex, Dietmar ^d   Kaderali, Lars ^a   Schackert, Gabriele ^d   Platzer, Matthias ^b   Klink, Barbara ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b FRITZ LIPMANN INSTITUTE   (Germany)

^c UNIVERSITY OF BERGEN   (Norway)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; MESSENGER RNA; TRANSCRIPTOME;

ADULT; ALLELE; ARTICLE; ASTROCYTOMA; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; CIC GENE; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; DNA SEQUENCE; EXON; FEMALE; FUBP1 GENE; GENE DELETION; GENE EXPRESSION REGULATION; HOMOZYGOTE; HUMAN; HUMAN TISSUE; IDH1 GENE; IDH2 GENE; MALE; MUTATION RATE; OLIGODENDROGLIOMA; POINT MUTATION; RNA SEQUENCE; TUMOR GENE; TUMOR SUPPRESSOR GENE;

ADULT; ALLELES; ASTROCYTOMA; CHROMOSOME DELETION; COHORT STUDIES; DNA HELICASES; DNA-BINDING PROTEINS; EXONS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; GLIOMA; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; OLIGODENDROGLIOMA; POINT MUTATION; REPRESSOR PROTEINS; SEQUENCE ANALYSIS, DNA; SEQUENCE ANALYSIS, RNA;

EID: 84884691994     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076623     Document Type: Article

References (42)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, (2007) WHO Classification of Tumours of the Central Nervous System; Bosman FT, Jaffe ES, Lakhani SR, Ohgaki H, eds. Lyon: International Agency for Research on Cancer (IARC) Press.
2. Bromberg JE, van den Bent MJ, (2009) Oligodendrogliomas: Molecular Biology and Treatment. Oncologist 14: 155-163. doi:10.1634/theoncologist.2008-0248. PubMed: 19182242.
3. Weiler M, Wick W, (2012) Molecular predictors of outcome in low-grade glioma. Curr Opin Neurol 25: 767-773. doi:10.1097/WCO.0b013e32835a0217. PubMed: 23160425.
4. Klink B, Schlingelhof B, Klink M, Stout-Weider K, Patt S, et al. (2010) Glioblastomas with oligodendroglial component- common origin of the different histological parts and genetic subclassification. Anal Cell Pathol (Amst) 33: 37-54. PubMed: 20966543.
5. Ohgaki H, Kleihues P, (2011) Genetic profile of astrocytic and oligodendroglial gliomas. Brain Tumor Pathol 28: 177-183. doi:10.1007/s10014-011-0029-1. PubMed: 21442241.
6. Riemenschneider MJ, Jeuken JW, Wesseling P, Reifenberger G, (2010) Molecular diagnostics of gliomas: state of the art. Acta Neuropathol 120: 567-584. doi:10.1007/s00401-010-0736-4. PubMed: 20714900.
7. Griffin CA, Burger P, Morsberger L, Yonescu R, Swierczynski S, et al. (2006) Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol 65: 988-994. doi:10.1097/01.jnen.0000235122.98052.8f. PubMed: 17021403.
8. Jenkins RB, Blair H, Ballman KV, Giannini C, Arusell RM, et al. (2006) A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66: 9852-9861. doi:10.1158/0008-5472.CAN-06-1796. PubMed: 17047046.
9. Cairncross G, Jenkins R, (2008) Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma. Cancer J 14: 352-357. doi:10.1097/PPO.0b013e31818d8178. PubMed: 19060598.
10. Kim YH, Nobusawa S, Mittelbronn M, Paulus W, Brokinkel B, et al. (2010) Molecular classification of low-grade diffuse gliomas. Am J Pathol 177: 2708-2714. doi:10.2353/ajpath.2010.100680. PubMed: 21075857.
11. van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJB, et al. (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organization for Research and Treatment of Cancer phase III trial. J Clin Oncol 24: 2715--2722. doi:10.1200/JCO.2005.04.6078. PubMed: 16782911.
12. Bettegowda C, Agrawal N, Jiao Y, Sausen M, Wood LD, et al. (2011) Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 333: 1453-1455. doi:10.1126/science.1210557. PubMed: 21817013.
13. Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, et al. (2012) Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 3: 709-722. PubMed: 22869205.
14. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H, (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174: 1149-1153. doi:10.2353/ajpath.2009.080958. PubMed: 19246647.
15. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, et al. (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: 765-773. doi:10.1056/NEJMoa0808710. PubMed: 19228619.
16. Idbaih A, Ducray F, Dehais C, Courdy C, Carpentier C, et al. (2012) SNP array analysis reveals novel genomic abnormalities including copy neutral loss of heterozygosity in anaplastic oligodendrogliomas. PLOS ONE 7: e45950. doi:10.1371/journal.pone.0045950. PubMed: 23071531.
17. Sahm F, Koelsche C, Meyer J, Pusch S, Lindenberg K, et al. (2012) CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas. Acta Neuropathol 123: 853-860. doi:10.1007/s00401-012-0993-5. PubMed: 22588899.
18. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, et al. (2010) A method and server for predicting damaging missense mutations. Nat Methods 7: 248-249. doi:10.1038/nmeth0410-248. PubMed: 20354512.
19. Schwarz JM, Rödelsperger C, Schuelke M, Seelow D, (2010) Mutation Taster evaluates disease-causing potential of sequence alterations. Nat Methods 7: 575-576. doi:10.1038/nmeth0810-575. PubMed: 20676075.
20. Reva B, Antipin Y, Sander C, (2011) Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res 39: e118. doi:10.1093/nar/gkr432. PubMed: 21727090.
21. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B, (2008) Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods 5: 621-628. doi:10.1038/nmeth.1226. PubMed: 18516045.
22. Yip S, Butterfield YS, Morozova O, Chittaranjan S, Blough MD, et al. (2012) Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol 226: 7-16. doi:10.1002/path.2995. PubMed: 22072542.
23. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, et al. (2012) The cBio Cancer Genomics Portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2: 401-404. doi:10.1158/2159-8290.CD-12-0095 PubMed: 22588877.
24. Labussière M, Idbaih A, Wang XW, Marie Y, Boisselier B, et al. (2010) All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology 74: 1886-1890. doi:10.1212/WNL.0b013e3181e1cf3a. PubMed: 20427748.
25. Berger AH, Knudson AG, Pandolfi PP, (2011) A continuum model for tumour suppression. Nature 476: 163-169. doi:10.1038/nature10275. PubMed: 21833082.
26. Knudson AG, (2002) Cancer genetics. Am J Med Genet 111: 96-102. doi:10.1002/ajmg.10320. PubMed: 12124744.
27. Vogelstein B, Kinzler KW, (2004) Cancer genes and the pathways they control. Nat Med 10: 789-799. doi:10.1038/nm1087. PubMed: 15286780.
28. Ollila J, Lappalainen I, Vihinen M, (1996) Sequence specificity in CpG mutation hotspots. FEBS Lett 396: 119-122. doi:10.1016/0014-5793(96)01075-7. PubMed: 8914970.
29. Nicholson P, Mühlemann O, (2010) Cutting the nonsense: the degradation of PTC-containing mRNAs. Biochem Soc Trans 38: 1615-1620. doi:10.1042/BST0381615. PubMed: 21118136.
30. Klink B, Miletic H, Stieber D, Huszthy PC, Valenzuela JA, et al. (2013) A Novel, Diffusely Infiltrative Xenograft Model of Human Anaplastic Oligodendroglioma with Mutations in FUBP1, CIC, and IDH1. PLOS ONE 8: e59773. doi:10.1371/journal.pone.0059773. PubMed: 23527265.
31. Lee CJ, Chan WI, Cheung M, Cheng YC, Appleby VJ, et al. (2002) CIC, a member of a novel subfamily of the HMG-box superfamily, is transiently expressed in developing granule neurons. Brain Res. Mol Brain Res 106: 151-156. doi:10.1016/S0169-328X(02)00439-4. PubMed: 12393275.
32. Yang D, Tewary P, de la Rosa G, Wei F, Oppenheim JJ, (2010) The alarmin functions of high-mobility group proteins. Biochim Biophys Acta 1799: 157-163. doi:10.1016/j.bbagrm.2009.11.002. PubMed: 20123077.
33. Ajuria L, Nieva C, Winkler C, Kuo D, Samper N, et al. (2011) Capicua DNA-binding sites are general response elements for RTK signaling in Drosophila. Development 138: 915-924. doi:10.1242/dev.057729. PubMed: 21270056.
34. Astigarraga S, Grossman R, Díaz-Delfín J, Caelles C, Paroush Z, et al. (2007) A MAPK docking site is critical for downregulation of Capicua by Torso and EGFR RTK signaling. EMBO J 26: 668-677. doi:10.1038/sj.emboj.7601532. PubMed: 17255944.
35. Roch F, Jiménez G, Casanova J, (2002) EGFR signalling inhibits Capicua-dependent repression during specification of Drosophila wing veins. Development 129: 993-1002. PubMed: 11861482.
36. Zhang J, Chen QM, (2012) Far upstream element binding protein 1: a commander of transcription, translation and beyond. Oncogene, 32: 2907-16. PubMed: 22926519.
37. Duncan R, Bazar L, Michelotti G, Tomonaga T, Krutzsch H, et al. (1994) A sequence-specific, single-strand binding protein activates the far upstream element of c-myc and defines a new DNA-binding motif. Genes Dev 8: 465-480. doi:10.1101/gad.8.4.465. PubMed: 8125259.
38. Hsiao HH, Nath A, Lin CY, Folta-Stogniew EJ, Rhoades E, et al. (2010) Quantitative characterization of the interactions among c-myc transcriptional regulators FUSE, FBP, and FIR. Biochemistry 49: 4620-4634.
39. Chien HL, Liao CL, Lin YL, (2011) FUSE binding protein 1 interacts with untranslated regions of Japanese encephalitis virus RNA and negatively regulates viral replication. J Virol 85: 4698-4706. doi:10.1128/JVI.01950-10. PubMed: 21367899.
40. Olanich ME, Moss BL, Piwnica-Worms D, Townsend RR, Weber JD, (2011) Identification of FUSE-binding protein 1 as a regulatory mRNA-binding protein that represses nucleophosmin translation. Oncogene 30: 77-86. doi:10.1038/onc.2010.404. PubMed: 20802533.
41. Irwin N, Baekelandt V, Goritchenko L, Benowitz LI, (1997) Identification of two proteins that bind to a pyrimidine-rich sequence in the 3'-untranslated region of GAP-43 mRNA. Nucleic Acids Res 25: 1281-1288. doi:10.1093/nar/25.6.1281. PubMed: 9092640.
42. Williams BY, Hamilton SL, Sarkar HK, (2000) The survival motor neuron protein interacts with the transactivator FUSE binding protein from human fetal brain. FEBS Lett 470: 207-210. doi:10.1016/S0014-5793(00)01320-X. PubMed: 10734235.